Streetbeat News

CADL

Candel Therapeutics, Inc.

https://www.candeltx.com

Industry

Biotechnology

Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. The company develops CAN-2409, which is in Phase II clinical trails for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the treatment of lung cancer, as well as has completed Phase Ib/II clinical trials for the treatment of high-grade glioma. It also develops CAN-3110, which is in Phase I clinical trials for the treatment of recurrent glioblastoma. The company was formerly known as Advantagene, Inc. and changed its name to Candel Therapeutics, Inc. in November 2020. The company was incorporated in 2003 and is based in Needham, Massachusetts.

Open

6.85

Mkt cap

219M

Volume

19M

High

7.14

P/E Ratio

-3.08

52-wk high

14.60

Low

6.20

Div yield

N/A

52-wk low

1.02

Candel Therapeutics Inc (NASDAQ:CADL) has announced an $80 million underwritten public offering of its common stock and pre-funded warrants, including 10 million shares at $6 per share and 3.33 million pre-funded warrants at $5.99 each.

Portfolio Pulse from

December 13, 2024 | 2:00 pm

Candel Therapeutics has announced the pricing of a public offering, selling 10,000,001 shares at $6.00 each and pre-funded warrants for 3,333,333 shares at $5.99 each. The offering is expected to raise approximately $80 million, with a closing date around December 16, 2024.

Portfolio Pulse from

December 13, 2024 | 4:15 am

Candel Therapeutics, a biopharmaceutical company, announced an $80 million public offering of its common stock and pre-funded warrants. The offering includes a 30-day option for underwriters to purchase an additional $12 million in shares. The completion and terms of the offering depend on market conditions.

Portfolio Pulse from

December 12, 2024 | 10:00 pm

Candel Therapeutics' stock surged by 68% after the company announced that its Phase III study of CAN-2409 combination therapy for prostate cancer met its primary goal compared to standard-of-care radiation therapy.

Portfolio Pulse from

December 12, 2024 | 4:45 pm

Candel Therapeutics' phase 3 trial for CAN-2409 in high-risk prostate cancer met its primary endpoint, showing a 14.5% improvement in disease-free survival over placebo. Despite financial challenges, this success supports a potential FDA submission by mid-2025.

Portfolio Pulse from

December 11, 2024 | 5:30 pm

Candel Therapeutics Inc (NASDAQ:CADL) announced positive Phase 3 trial results for its immunotherapy CAN-2409, showing significant improvement in disease-free survival for localized prostate cancer patients.

Portfolio Pulse from

December 11, 2024 | 2:00 pm

Candel Therapeutics announced that its experimental prostate cancer drug achieved the primary endpoint in a late-stage trial, resulting in a 64% increase in the company's shares during premarket trading.

Portfolio Pulse from

December 11, 2024 | 12:30 pm

Candel Therapeutics announced that its CAN-2409 viral immunotherapy achieved the primary endpoint in a Phase 3 trial for prostate cancer, showing significantly improved disease-free survival.

Portfolio Pulse from

December 11, 2024 | 12:15 pm

Candel Therapeutics is advocating for a new approach in cancer treatment, focusing on immunotherapies that utilize the body's immune system, moving away from traditional methods like surgery, radiation, and chemotherapy.

Portfolio Pulse from

November 29, 2024 | 3:45 pm

Candel Therapeutics CEO Paul Peter Tak emphasizes the importance of prioritizing patient needs in cancer treatment. This approach is central to the company's mission and Tak's career, which combines scientific innovation with personal resilience.

Portfolio Pulse from

November 22, 2024 | 3:15 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.